The conditional benefit of being alive and disease free at 2 years after transplant: a long term survival evaluation among 456 patients affected by acute myeloid leukemia
Risk factors for relapse and non-relapse mortality (NRM) in the first years after allogeneic hematopoietic stem cells transplant (allo-HSCT) for acute myeloid leukemia (AML) are well known, but their correlation with long-term survivorship is unclear. …